Nature Communications

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial

2025-10-07

Full text

DOI https://doi.org/10.1038/s41467-025-63978-y